Zolgensma Novartis Pharmaceuticals Australia Pty Ltd
Product name
Zolgensma
Accepted date
Nov-2024
Active ingredients
onasemnogene abeparvovec
Proposed indication
Zolgensma is a gene therapy for children who have spinal muscular atrophy (SMA) with alterations in the SMN1 gene.
Application type
C (new indication)
Publication date
Nov-2024